Details of the Drug

General Information of Drug (ID: DMBSHMF)

Drug Name
Boceprevir
Synonyms
Boceprevir; Victrelis; 394730-60-0; SCH 503034; EBP 520; UNII-89BT58KELH; SCH-503034; 89BT58KELH; CHEBI:68621; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 519.7
Topological Polar Surface Area (xlogp) 3.1
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Chemical Identifiers
Formula
C27H45N5O5
IUPAC Name
(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
Canonical SMILES
CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C
InChI
InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
InChIKey
LHHCSNFAOIFYRV-DOVBMPENSA-N
Cross-matching ID
PubChem CID
10324367
ChEBI ID
CHEBI:68621
CAS Number
394730-60-0
DrugBank ID
DB08873
TTD ID
D0V3YT
VARIDT ID
DR01333
INTEDE ID
DR0218
ACDINA ID
D00073

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) TTHC7JD POLG_HCV1 Modulator [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [5]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Boceprevir
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Daclatasvir DMSFK9V Major Decreased metabolism of Boceprevir caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [34]
GS-9857 DMYU6P5 Moderate Decreased clearance of Boceprevir due to the transporter inhibition by GS-9857. Hepatitis virus infection [1E50-1E51] [35]
Coadministration of a Drug Treating the Disease Different from Boceprevir (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Decreased metabolism of Boceprevir caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [36]
Arn-509 DMT81LZ Major Increased metabolism of Boceprevir caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [37]
Gilteritinib DMWQ4MZ Major Decreased metabolism of Boceprevir caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [38]
Oliceridine DM6MDCF Major Decreased metabolism of Boceprevir caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [39]
Ivabradine DM0L594 Major Decreased metabolism of Boceprevir caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [40]
Bedaquiline DM3906J Moderate Decreased metabolism of Boceprevir caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [41]
Erdafitinib DMI782S Major Decreased metabolism of Boceprevir caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [42]
Pexidartinib DMS2J0Z Major Decreased metabolism of Boceprevir caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [43]
Talazoparib DM1KS78 Moderate Decreased clearance of Boceprevir due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [44]
HKI-272 DM6QOVN Major Decreased metabolism of Boceprevir caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
LY2835219 DM93VBZ Major Decreased metabolism of Boceprevir caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [46]
Palbociclib DMD7L94 Major Decreased metabolism of Boceprevir caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Macitentan DMP79A1 Major Decreased metabolism of Boceprevir caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [48]
PF-04449913 DMSB068 Major Decreased metabolism of Boceprevir caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [49]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Boceprevir caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [50]
Revefenacin DMMP5SI Moderate Decreased clearance of Boceprevir due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [51]
Levomilnacipran DMV26S8 Major Decreased metabolism of Boceprevir caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [52]
Fidaxomicin DMFP6MV Minor Decreased clearance of Boceprevir due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [40]
Regorafenib DMHSY1I Moderate Decreased metabolism of Boceprevir caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [40]
Intedanib DMSTA36 Moderate Decreased clearance of Boceprevir due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [53]
Osilodrostat DMIJC9X Major Decreased metabolism of Boceprevir caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [54]
OPC-34712 DMHG57U Major Decreased metabolism of Boceprevir caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [55]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Boceprevir caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [56]
Ingrezza DMVPLNC Major Additive CNS depression effects by the combination of Boceprevir and Ingrezza. Dystonic disorder [8A02] [57]
Oestradiol valerate and dienogest DMZK0FQ Major Increased metabolism of Boceprevir caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [58]
Stiripentol DMMSDOY Moderate Decreased metabolism of Boceprevir caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [34]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Boceprevir caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [59]
Cannabidiol DM0659E Minor Decreased metabolism of Boceprevir caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [34]
Bay 80-6946 DMLOS5R Major Decreased metabolism of Boceprevir caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [60]
Tazemetostat DMWP1BH Major Decreased metabolism of Boceprevir caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [61]
Mirabegron DMS1GYT Minor Decreased metabolism of Boceprevir caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [62]
Ripretinib DM958QB Major Decreased metabolism of Boceprevir caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [40]
MK-1439 DM215WE Minor Decreased metabolism of Boceprevir caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Fostemsavir DM50ILT Moderate Decreased metabolism of Boceprevir caused by Fostemsavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Dolutegravir DMCZGRE Minor Decreased metabolism of Boceprevir caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Aliskiren DM1BV7W Moderate Decreased metabolism of Boceprevir caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [66]
Levamlodipine DM92S6N Moderate Decreased metabolism of Boceprevir caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [59]
TP-434 DM5A31S Minor Decreased metabolism of Boceprevir caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [67]
Suvorexant DM0E6S3 Major Decreased metabolism of Boceprevir caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [40]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Boceprevir caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [68]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Boceprevir caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [69]
Naloxegol DML0B41 Major Decreased metabolism of Boceprevir caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [40]
Pemigatinib DM819JF Major Decreased metabolism of Boceprevir caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [70]
Brigatinib DM7W94S Major Decreased metabolism of Boceprevir caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [71]
Ceritinib DMB920Z Major Decreased metabolism of Boceprevir caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [40]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Boceprevir caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [72]
PF-06463922 DMKM7EW Major Decreased metabolism of Boceprevir caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [73]
Osimertinib DMRJLAT Major Decreased metabolism of Boceprevir caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [74]
Pralsetinib DMWU0I2 Major Decreased metabolism of Boceprevir caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [75]
Capmatinib DMYCXKL Major Decreased metabolism of Boceprevir caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [76]
Selpercatinib DMZR15V Major Decreased metabolism of Boceprevir caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [77]
Idelalisib DM602WT Moderate Decreased clearance of Boceprevir due to the transporter inhibition by Idelalisib. Mature B-cell leukaemia [2A82] [78]
GDC-0199 DMH0QKA Major Decreased metabolism of Boceprevir caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [79]
IPI-145 DMWA24P Major Decreased metabolism of Boceprevir caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [80]
Acalabrutinib DM7GCVW Major Decreased metabolism of Boceprevir caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [81]
Ibrutinib DMHZCPO Major Decreased metabolism of Boceprevir caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [40]
Ponatinib DMYGJQO Major Decreased metabolism of Boceprevir caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [40]
Arry-162 DM1P6FR Moderate Decreased clearance of Boceprevir due to the transporter inhibition by Arry-162. Melanoma [2C30] [40]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Boceprevir caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [82]
Selumetinib DMC7W6R Major Decreased metabolism of Boceprevir caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [83]
LGX818 DMNQXV8 Major Decreased metabolism of Boceprevir caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [84]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Boceprevir caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [40]
Ubrogepant DM749I3 Major Decreased metabolism of Boceprevir caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [85]
Rimegepant DMHOAUG Moderate Decreased metabolism of Boceprevir caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [86]
Siponimod DM2R86O Major Decreased metabolism of Boceprevir caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [40]
Fedratinib DM4ZBK6 Major Decreased metabolism of Boceprevir caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [34]
Ruxolitinib DM7Q98D Major Decreased metabolism of Boceprevir caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [87]
Vorapaxar DMA16BR Major Decreased metabolism of Boceprevir caused by Vorapaxar mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [40]
Netupitant DMEKAYI Minor Decreased metabolism of Boceprevir caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [88]
E-2007 DMJDYNQ Minor Decreased metabolism of Boceprevir caused by E-2007 mediated inhibition of CYP450 enzyme. Neuropathy [8C0Z] [34]
Entrectinib DMMPTLH Major Decreased metabolism of Boceprevir caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [34]
S-297995 DM26IH8 Moderate Decreased metabolism of Boceprevir caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [34]
Olaparib DM8QB1D Major Decreased metabolism of Boceprevir caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [40]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Boceprevir caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [89]
Istradefylline DM20VSK Major Decreased metabolism of Boceprevir caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [90]
Abametapir DM2RX0I Moderate Decreased metabolism of Boceprevir caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [91]
Lefamulin DME6G97 Major Decreased metabolism of Boceprevir caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [92]
Enzalutamide DMGL19D Major Increased metabolism of Boceprevir caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [37]
Darolutamide DMV7YFT Moderate Decreased metabolism of Boceprevir caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [93]
Riociguat DMXBLMP Moderate Decreased clearance of Boceprevir due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [40]
Upadacitinib DM32B5U Major Decreased metabolism of Boceprevir caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [94]
Tofacitinib DMBS370 Major Decreased metabolism of Boceprevir caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [40]
Voxelotor DMCS6M5 Major Decreased metabolism of Boceprevir caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [95]
LDE225 DMM9F25 Major Decreased metabolism of Boceprevir caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [96]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Boceprevir caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [34]
Larotrectinib DM26CQR Major Decreased metabolism of Boceprevir caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [40]
LEE011 DMMX75K Major Decreased metabolism of Boceprevir caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [34]
Pomalidomide DMTGBAX Moderate Decreased clearance of Boceprevir due to the transporter inhibition by Pomalidomide. Systemic sclerosis [4A42] [40]
Fostamatinib DM6AUHV Major Decreased metabolism of Boceprevir caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [97]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Boceprevir due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [89]
As-1670542 DMV05SW Moderate Decreased metabolism of Boceprevir caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [34]
Cabozantinib DMIYDT4 Major Decreased metabolism of Boceprevir caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [40]
Elagolix DMB2C0E Major Decreased metabolism of Boceprevir caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [98]
Fluticasone DMGCSVF Major Decreased metabolism of Boceprevir caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [99]
Betrixaban DM2C4RF Moderate Decreased clearance of Boceprevir due to the transporter inhibition by Betrixaban. Venous thromboembolism [BD72] [100]
⏷ Show the Full List of 95 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Boceprevir 200 mg capsule 200 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7876).
2 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
3 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4 Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
5 Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother. 2013 Jun;57(6):2582-8.
6 Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49.
7 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
8 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
9 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
10 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
11 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
12 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
13 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
14 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
15 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
16 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
17 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
18 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
19 Drug Interactions Flockhart Table
20 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
21 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
22 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
23 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
24 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
25 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
26 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
27 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
28 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
29 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
30 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
31 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
32 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
33 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
34 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
35 Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Gilead Sciences, Foster City, CA.
36 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
37 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
38 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
39 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
40 Cerner Multum, Inc. "Australian Product Information.".
41 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
42 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
43 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
44 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
45 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
46 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
47 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
49 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
50 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
51 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
52 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
53 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
54 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
55 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
56 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
57 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
58 Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
59 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
60 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
61 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
62 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
63 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
64 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
65 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
66 Canadian Pharmacists Association.
67 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
68 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
69 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
70 Product Information. Pemazyre (pemigatinib). Incyte Corporation, Wilmington, DE.
71 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
72 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
73 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
74 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
75 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
76 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
77 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
78 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
79 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
80 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
81 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
82 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
83 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
84 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
85 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
86 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
87 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
88 Product Information. Akynzeo (netupitant-palonosetron). Eisai Inc, Woodcliff Lake, NJ.
89 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
90 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
91 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
92 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
93 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
94 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
95 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
96 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
97 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
98 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
99 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
100 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.